Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 8;4(2):e325.
doi: 10.1212/NXI.0000000000000325. eCollection 2017 Mar.

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS

Sibylle C Hodecker  1 , Klarissa H Stürner  1 , Veit Becker  1 , Birte Elias-Hamp  1 , Brigitte Holst  1 , Manuel A Friese  1 , Christoph Heesen  1
Affiliations

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS

Sibylle C Hodecker et al. Neurol Neuroimmunol Neuroinflamm. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure. Serial MRIs of the brain
Serial axial postcontrast T1-weighted magnetic resonance images of the brain of case 1 (A–C) and case 2 (D–F). (A) In February 2015, a T1-weighted image showed right subcortical occipital lesion (hyperintense in T2-weighted images) with subtle contrast enhancement suggestive of progressive multifocal leukoencephalopathy (PML) in a clinically asymptomatic patient. (B) Four months later, MRI showed progression of the contrast-enhancing occipital lesion, and maraviroc treatment was initiated. (C) Six months after start of maraviroc, MRI shows regression of PML–immune reconstitution inflammatory syndrome (IRIS) with no detectable contrast enhancement. (D) A routine MRI in February 2015 showed disseminated contrast-enhancing lesions in the cerebellum suggestive of PML in a clinically asymptomatic patient. (E) In May 2015, a T1-weighted image showed extensive IRIS after discontinuation of maraviroc. (F) Eleven months after the initial diagnosis of PML and after 8 months of maraviroc treatment, multiple disseminated contrast-enhancing lesions in the cerebellum are still detectable.
See this image and copyright information in PMC

References

    1. Bloomgren G, Richman S, Hotermans C, et al. . Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870–1880. - PubMed
    1. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011;77:1061–1067. - PMC - PubMed
    1. Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 2014;370:486–488. - PMC - PubMed
    1. Plavina T, Subramanyam M, Bloomgren G, et al. . Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:802–812. - PMC - PubMed

LinkOut - more resources